188 related articles for article (PubMed ID: 17598372)
1. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients.
Espinosa M; Arenas MD; Aumente MD; Barril G; Buades JM; Aviles B; Carretero D; Alvarez-Lara MA; Carnicer F; Martin-Malo A; Aljama P
Clin Nephrol; 2007 Jun; 67(6):366-73. PubMed ID: 17598372
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
[TBL] [Abstract][Full Text] [Related]
4. Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C.
Durante-Mangoni E; Parrella A; Iossa D; Andini R; Molaro R; Battimelli C; Sodano G; Utili R
Clin Drug Investig; 2014 Dec; 34(12):871-8. PubMed ID: 25349040
[TBL] [Abstract][Full Text] [Related]
5. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
Lee S; Kim IH; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Lee CS; Choi CS; Cho EY; Kim HC
Intervirology; 2010; 53(3):146-53. PubMed ID: 20068348
[TBL] [Abstract][Full Text] [Related]
7. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.
Barril G; Quiroga JA; Sanz P; Rodrìguez-Salvanés F; Selgas R; Carreño V
Aliment Pharmacol Ther; 2004 Jul; 20(1):37-44. PubMed ID: 15225169
[TBL] [Abstract][Full Text] [Related]
9. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
[TBL] [Abstract][Full Text] [Related]
10. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
[TBL] [Abstract][Full Text] [Related]
11. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C?
Potthoff A; Wiegand J; Lüth JB; Wedemeyer H; Manns MP; Tillmann HL
Clin Nephrol; 2005 Mar; 63(3):232-5. PubMed ID: 15786827
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
13. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
Ozgenc F; Dikici B; Targan S; Doganci T; Akman S; Aydogdu S; Yagci RV
Antivir Ther; 2004 Feb; 9(1):23-6. PubMed ID: 15040533
[TBL] [Abstract][Full Text] [Related]
18. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
19. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
Akhan SC; Kalender B; Ruzgar M
Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
[TBL] [Abstract][Full Text] [Related]
20. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
